Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

European Commission Grants $6M to Develop New Hemophilia A Treatment

Note: The following is an edited press release from Sernova Corp. The original release can be read in its entirety here. Sernova Corp., a clinical stage regenerative medicine company, announced on Monday, December 21, 2015, that the European Commission’s Horizon 2020 program has awarded a Euro 5.6M ($6.1M USD) grant to a consortium consisting of […]

Industry News

Arsia and Biogen Team Up to Develop Sub-Q Hemophilia Treatment

Note: The following is an edited press release from Arsia Therapeutics, Inc. The original release can be read here. Arsia Therapeutics, Inc., a Cambridge based company, announced a collaboration with Biogen on December 16, 2015. Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments […]

Industry News

FDA Approves First Recombinant von Willebrand Factor

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed […]

Industry News

Phase I Study Results for Once-Monthly Subcutaneous Hemophilia Treatment

Note: The following is an edited press release from Alnylam. The original release can be read in its entirety here. Alnylam Pharmaceuticals, Inc. announced on December 7, 2015 positive results from its ongoing Phase 1 clinical study with fitusiran (fi-TOO-si-ran), the recommended International Nonproprietary Name (INN) for ALN-AT3. Fitusiran is an investigational RNAi therapeutic targeting […]

Industry News

FDA Approves Twice-Weekly Hemophilia A Treatment

Note: The following is an edited version of a press release originally published by Baxalta. The original release can be read here. Baxalta Incorporated announced on Monday, November 16, 2015, that the U.S. Food and Drug Administration (FDA) has approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia […]

Industry News

FDA Approves First Factor X Concentrate for Treatment of a Rare Hereditary Bleeding Disorder

Note: The following is an edited version of a press release originally published by the US Food and Drug Administration (FDA). The original release can be read here. The U.S. Food and Drug Administration announced on Tuesday, October 20, 2015, the approval of  Coagadex, Coagulation Factor X (Human), for hereditary Factor X (10) deficiency. Until […]

Industry News

New Study Open To Hemophilia B Community

Novo Nordisk, along with the Coalition for Hemophilia B, Hemophilia Federation of America, and National Hemophilia Foundation have announced the B-HERO-S (Bridging Hemophilia Experiences Results and Opportunities into Solutions) study open to all patients with hemophilia B and the caregivers of children with hemophilia B. About the Study Building on the success of the original […]

Industry News

FDA Approves Fast Track Designation for New Hemophilia B Treatment

Note: This is an edited form of a press release from Dimension Therapeutics, Inc. To read the original release in its entirety, click here. Dimension Therapeutics, Inc. announced on Thursday, September 17 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, DTX101, for the treatment of […]

Industry News

FDA Approves New Octapharma Treatment For Patients With Hemophilia A

Note: This is an edited form of a press release from Octapharma. To read the original release in its entirety, click here. Octapharma USA announced on September 15, 2015, that the U.S. Food and Drug Administration (FDA) has approved NUWIQ®, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The NUWIQ® […]

Industry News

FDA Grants Breakthrough Therapy for Subcutaneous Inhibitor Treatment

Note: This is an edited form of a press release from Genentech. To read the original release in its entirety, click here. Genentech announced on Friday, September 4, 2015, that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013, RO5534262) for the prophylactic treatment of people who are 12 years […]

Page 5 of 2112345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community